Amplification at 9p in cervical carcinoma by comparative genomic hybridization

Kowan J. Jee\textsuperscript{a}, Young Tak Kim\textsuperscript{b}, Kyu Rae Kim\textsuperscript{c}, Yan Aalto\textsuperscript{a} and Sakari Knuttila\textsuperscript{a,*}
\textsuperscript{a} Department of Medical Genetics, Haartman Institute and Helsinki University Central Hospital, University of Helsinki, Finland
\textsuperscript{b} Department of Obstetrics and Gynaecology, University of Ulsan, College of Medicine, ASAN Medical Center, Seoul, Korea
\textsuperscript{c} Department of Pathology, University of Ulsan, College of Medicine, ASAN Medical Center, Seoul, Korea

Accepted 14 March 2001

DNA copy number changes were studied by comparative genomic hybridization on 10 tumor specimens of squamous cell carcinoma of cervix obtained from Korean patients. DNA was extracted from paraffin-embedded sections after removal of non-malignant cells by microdissection technique. Copy number changes were found in 8/10 tumors. The most frequent changes were chromosome 19 gains ($n=6$) and losses on chromosomes 4 ($n=4$), 5 ($n=3$), and 3p ($n=3$). A novel finding was amplification in chromosome arm 9p21-pter in 2 cases. Gains in 1, 3q, 5p, 8q, 16p, 17, and 20q and losses at 2q, 6p, 8p, 9q, 10p, 11, 13, 16q, and 18q were observed in at least one of the cases.

Keywords: Cervical cancer, CGH, amplification at 9p21-pter

1. Introduction

Carcinoma of the uterine cervix is the second most common female malignancy word-wide that causes high morbidity and mortality rate in women and ranks first in incidence among malignant tumors of Korean women according to the data from Korean Cancer Registry. Specific types of human papilloma virus (HPV) are known to be the principal etiologic agents for cervical cancer [1–3]. Cytogenetic studies of primary cervical tumors have indicated nonrandom structural changes, particularly on chromosomes 1, 3, 4 or 5, 8, 11 and 17 [4,5]. Comparative genomic hybridization (CGH) in cervical cancer has shown recurrent DNA copy number gains at 1q, 3q, 5p, 8q, 15q, and 20, and losses at 3p, 4p, 6q, 11q, and 13q [1,6–9]. We used CGH to analyze primary tumors in 10 Korean cases of squamous cell carcinoma of cervix (SCC). Among the numerous DNA sequence copy number changes we detected, recurrent high-level amplification at 9p stands out as a significant novel finding.

2. Materials and methods

2.1. Specimens

All of our samples were collected in Korea. Ten paraffin-embedded cervical tumor tissue specimens obtained from radical hysterectomies were analyzed using CGH. The tumor grade and stage were identified according to the International Federation of Gynecology and Obstetrics (FIGO) criteria. The diagnoses were made by the pathologist (K.R. Kim) in the Department of Pathology, ASAN Medical Center, Seoul, Korea. Table 1 shows clinical data of all cases.

2.2. DNA extraction

High molecular weight DNA was extracted from archival tissue samples by microdissection as described by Abeln et al. [10]. Briefly, tumor cells were collected after removal of stroma by scraping with a clean scalpel from three unstained slide sections of 10 $\mu$m thickness. The tumor cells were transferred to a microcentrifuge tube containing digestion buffer, which was incubated overnight at 45°C. After addition of proteinase K, the samples were incubated in water bath at 100°C for 10 minutes and centrifuged. After centrifuge the supernatant was transferred to a sterile tube.
2.3. Comparative genomic hybridization

CGH was performed as described previously [11]. Normal DNA was extracted from peripheral blood of healthy donors and labeled with Texas red dCTP and dUTP (DuPont, Boston, MA) in a standard nick-translation reaction. The tumor DNA was labeled with a mixture of fluorescein dCTP and dUTP (DuPont). Equal amounts of the labeled tumor and reference DNA were hybridized onto normal metaphase slides. Before hybridization, the DNA was denatured for 5 minutes at 75°C and metaphase slides were treated in 70, 80, and 100% ethanol series, and denatured at 65°C for 2 minutes in formamide solution. Hybridization was performed in a moisture chamber at 37°C for 48 hours and washing was performed in formamide solutions. Then the slides were mounted with antifading medium containing a counterstain (Vector Laboratories, Burlingame, CA) and analyzed using the ISIS digital image analysis system (MetaSystems GmbH, Altussheim, Germany). The average ratio profile was calculated as a mean value obtained from 10 to 15 metaphase spreads. Based on previous experience, we used 1.17 and 0.85 as cut-off levels for gains and losses, respectively. The region was considered as highly amplified when the ratio exceeded 1.5.

3. Results

Eight of the 10 specimens (Table 1, Fig.1) showed DNA copy number changes with a mean of 5.1 aberrations per specimen (range: 0–18). The most common gains were found in 19 (6 cases), 3q (2), 8q (2), 9p (2), 16p (2), and 20q (2). High-level amplifications were seen at 5p14-ter (1 case), 20q11 (2), and 9p21-ter (2). The most common losses were observed at 4q (4 cases), 3p (3), and 5 (3). Figure 2 shows high-level amplifications at 9p (green-to-red ratio higher than 2.5) in 2 cases (nos 3 and 4).

4. Discussion

Our novel finding is a recurrent high-level amplification in the short arm of chromosome 9. In 2 out of 12 cases the level of this amplification was higher than that in any other of the detected gains.

In all types of tumor, 9p is one the most common areas of DNA copy number losses [12], whereas DNA copy number amplifications are relatively rare [13], online access http://www.helsinki.fi/~lgl_www/CMG.html. In previous studies, gains at 9p have not been considered to be a significant recurrent change in SCC, even though this gain (not high-level amplifica-
tion) has been detected in about 5–7% of cases [1,6,8]. Other recurrent gains (3q, 8q, 16p, 19, and 20q) and losses (4q, 3p, 5, 6q, 11q, 13, and 16q) in SCC have been reported also by others [1,6,8].

So far no genes located at 9p have been implicated in SCC. Some of the genes, such as TEK (9p21, endothelial cell surface receptor tyrosine kinase) and BAG1 (9p12, BCL2-associated Anthano Gene 1) encode proteins that have oncogenic or anti-apoptotic functions [14]. Although CGH showed the DNA sequence amplification, it cannot be ruled out that the amplicon includes also lost gene sequences from, for instance, suppressor genes CDKN2A and CDKN2B. In the characterization of DNA copy number amplifications by PCR with polymorphic markers, Wolf et al. [15] demonstrated that, in addition to highly amplified sequences, the 12q amplicon in sarcomas contains non-amplified and even lost sequences. Consequently, the aim of
molecular characterization of 9p amplicon should be widened from identification of amplified target genes to detection of lost genes.

Human papilloma virus (HPV) infection is considered to be the initial event in cervical carcinoma [2,3,16]. Given that we studied only Korean patients, it is relevant to question whether ethnic differences between HPV subtypes could account for the divergent findings we and others report regarding 9p amplification. Incidence studies around the world indicate that HPV16 is the most frequent subtype (in 5% of the tumors), followed by HPV18. It should be noted that in Korean population HPV33 is more prevalent than HPV18 and there are also specific variants of HPV16 [16,17]. Further studies are needed to determine whether these differences are associated with the presence of 9p amplification.

References

[1] K. Heselmeyer, M. Macville, E. Schrock, H. Blegen, A.C. Hellström, K. Shah, G. Auer and T. Ried, Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q, *Genes Chromosomes Cancer* 19 (1997), 233–240.

[2] C.S. Herrington, Human papillomaviruses and cervical neoplasia. I. Classification, virology, pathology and epidemiology, *J. Clin. Pathol.* 47 (1994), 1066–1072.

[3] J. Ponten, H.O. Adami, R. Bergström, J. Dillner, L.G. Friberg, L. Gustafsson, A.B. Miller, D.M. Parkin, P. Saparen and D. Trichopoulos, Strategies for global control of cervix cancer, *Int. J. Cancer* 60 (1995), 1–26.

[4] N.B. Atkin, M.C. Baker and M.F. Fox, Chromosome changes in 43 carcinomas of the cervix uteri, *Cancer Genet. Cytogenet.* 44 (1990), 229–241.

[5] A. Thein, M. Trková, M. Fox and J. Parrington, The application of comparative genomic hybridization to previously karyotyped cervical cancer cell lines, *Cancer Genet. Cytogenet.* 116 (2000), 59–65.

[6] K. Heselmeyer, E. Schröck, S. du Manoir, H. Blegen, K. Shah, R. Steinbeck, G. Auer and T. Ried, Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix, *Proc. Natl. Acad. Sci. USA* 93 (1996), 479–484.

[7] M. Aubele, H. Zitzelsberger, U. Schenck, A. Walch, H. Höfler and M. Werner, Distinct cytogenetic alterations in squamous intraepithelial lesions of the cervix revealed by laser-assisted microdissection and comparative genomic hybridization, *Cancer* 84 (1998), 375–379.

[8] A. Dellas, J. Torhorst, F. Jiang, J. Proffitt, E. Schultheiss, W. Holzgreve, G. Sauter, M. J. Mihatsch and H. Moch, Prognostic value of genomic alterations in invasive cervical squamous cell carcinoma of clinical stage IB detected by comparative genomic hybridization, *Cancer Res.* 59 (1999), 3475–3479.

[9] M. Kirchhoff, H. Rose, B. L. Petersen, J. Maahr, T. Gerdes, C. Lundsteen, T. Bryndorf, N. Kryger-Baggesen, L. Christiansen, S.A. Engelholm and J. Philip, Comparative genomic hybridization reveals a recurrent pattern of chromosomal aberrations in severe dysplasia/carcinoma in situ of the cervix and in advanced-stage cervical carcinoma, *Genes Chromosomes Cancer* 24 (1999), 144–150.

[10] E.C. Abeln, W.E. Corver, N.J. Kuipers-Dijkshoorn, G.J. Fleuren and C.J. Cornelisse, Molecular genetic analysis of flow-sorted ovarian tumour cells: improved detection of loss of heterozygosity, *Br. J. Cancer* 70 (1994), 255–262.

[11] W. El-Rifai, M.L. Larramendy, A.-M. Björkqvist, S. Hemmer and S. Knuutila, Optimization of comparative genomic hybridization using fluorochrome conjugated to dCTP and dUTP nucleotides, *Lab. Invest.* 77 (1997), 699–700.

[12] S. Knuutila, Y. Aalto, K. Autio, A.-M. Björkqvist, W. El-Rifai, S. Hemmer, T. Huhta, E. Korttunen, S. Kauru-Kuhlefelt, M.L. Larramendy, T. Lushnikova, O. Monni, H. Pere, J. Tapper, M. Taskkanen, A. Varis, V.-M. Wasenius, M. Wolf and Y. Zhu, DNA copy number losses in human neoplasms. Review, *Am. J. Pathol.* 155 (1999), 683–694.
[13] S. Knuutila, A.-M. Björkqvist, K. Autio, M. Tarkkanen, M. Wolf, O. Monni, J. Szymanska, M.L. Larramendy, J. Tapper, H. Pere, W. El-Rifai, S. Hemmer, V.-M. Wassenius, V. Vidgren and Y. Zhu, DNA copy number amplifications in human neoplasms. Review of comparative genomic hybridization studies, *Am. J. Pathol.* **152** (1998), 1107–1123.

[14] S. Takayama, K. Kochel, S. Irie, J. Inazawa, T. Abe, T. Sato, T. Druck, T. Huebner and J.C. Reed, Cloning of cDNAs encoding the human BAG1 protein and localization of the human BAG1 gene to chromosome 9p12, *Genomics* **35** (1996), 494–498.

[15] M. Wolf, L.A. Aaltonen, J. Szymanska, M. Tarkkanen, C. Blomqvist, J.-M. Berner, O. Myklebost and S. Knuutila, Complexity of 12q13-22 amplicon in liposarcoma: microsatellite repeat analysis, *Genes Chromosomes Cancer* **18** (1997), 66–70.

[16] A. Hidalgo, C. Schewe, S. Petersen, M. Salcedo, P. Gariglio, K. Schluns, M. Dietel and I. Petersen, Human papilloma virus status and chromosomal imbalances in primary cervical carcinomas and tumour cell lines, *Eur. J. Cancer* **36** (2000), 542–548.

[17] J.S. Park, E.S. Hwang, C.J. Lee, C.J. Kim, J.G. Rha, S.J. Kim, S.E. Namkoong and S.J. Um, Mutational and functional analysis of HPV-16 URR derived from Korean cervical neoplasia, *Gynecol. Oncol.* **74** (1999), 23–29.